Suppr超能文献

唐氏综合征中的衰老与阿尔茨海默病神经病理学的发展

Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

作者信息

Head Elizabeth, Lott Ira T, Wilcock Donna M, Lemere Cynthia A

机构信息

Sanders Brown Center on Aging, University of Kentucky, 800 South Limestone Street, Lexington, KY, 40536, USA.

出版信息

Curr Alzheimer Res. 2016;13(1):18-29. doi: 10.2174/1567205012666151020114607.

Abstract

Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss. There is also evidence of potential compensatory responses in DS that benefit the brain and delay the onset of dementia after there is sufficient neuropathology for a diagnosis of AD. This review describes some of the existing literature and also highlights gaps in our knowledge regarding AD neuropathology in DS. It will be critical in the future to develop networked brain banks with standardized collection procedures to fully characterize the regional and temporal pathological events associated with aging in DS. As more information is acquired regarding AD evolution in DS, there will be opportunities to develop interventions that are age-appropriate to delay AD in DS.

摘要

21号染色体在唐氏综合征中会出现三体复制,该染色体包含几个被认为在阿尔茨海默病神经病理学发展中起关键作用的基因。21号染色体上淀粉样前体蛋白(APP)基因的过度表达会导致唐氏综合征患者早期出现β-淀粉样蛋白(Aβ)斑块。除了Aβ积累外,中年唐氏综合征患者还会出现神经原纤维缠结、脑血管病变、白质病变、氧化损伤、神经炎症和神经元丢失。也有证据表明唐氏综合征中存在潜在的代偿反应,在有足够的神经病理学表现可诊断为阿尔茨海默病后,这些反应对大脑有益并延缓痴呆症的发作。本综述描述了一些现有文献,也突出了我们在唐氏综合征中阿尔茨海默病神经病理学知识方面的空白。未来,建立具有标准化采集程序的联网脑库对于全面描述与唐氏综合征衰老相关的区域和时间病理事件至关重要。随着获得更多关于唐氏综合征中阿尔茨海默病演变的信息,将有机会开发适合年龄的干预措施来延缓唐氏综合征患者的阿尔茨海默病发病。

相似文献

1
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.
Curr Alzheimer Res. 2016;13(1):18-29. doi: 10.2174/1567205012666151020114607.
2
[Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Yakugaku Zasshi. 2017;137(7):801-805. doi: 10.1248/yakushi.16-00236-2.
3
HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.
Free Radic Biol Med. 2017 Oct;111:262-269. doi: 10.1016/j.freeradbiomed.2016.10.508. Epub 2016 Nov 10.
4
Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease.
Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):a024539. doi: 10.1101/cshperspect.a024539.
5
Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.
PLoS One. 2010 May 20;5(5):e10659. doi: 10.1371/journal.pone.0010659.
7
Untangle the mystery behind DS-associated AD - Is APP the main protagonist?
Ageing Res Rev. 2023 Jun;87:101930. doi: 10.1016/j.arr.2023.101930. Epub 2023 Apr 7.
8
Evidence against the overexpression of APP in Down syndrome.
IUBMB Life. 2006 Feb;58(2):103-6. doi: 10.1080/15216540600644853.
9
Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Acta Neuropathol. 2019 Dec;138(6):913-941. doi: 10.1007/s00401-019-02053-5. Epub 2019 Aug 14.
10
Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice.
Brain Behav Immun. 2018 Oct;73:235-251. doi: 10.1016/j.bbi.2018.05.008. Epub 2018 May 31.

引用本文的文献

1
Vertebrate and Invertebrate Animal Models for the Study of Down Syndrome.
Int J Mol Sci. 2025 Aug 21;26(16):8092. doi: 10.3390/ijms26168092.
2
Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites.
Alzheimers Dement. 2025 Aug;21(8):e70612. doi: 10.1002/alz.70612.
4
Interferon signaling modulates Down syndrome-associated Alzheimer's disease pathology in a mouse model.
iScience. 2025 Jul 16;28(8):113130. doi: 10.1016/j.isci.2025.113130. eCollection 2025 Aug 15.
5
Longitudinal diffusion tensor imaging correlates with amyloid burden in Down syndrome.
Alzheimers Dement. 2025 Aug;21(8):e70572. doi: 10.1002/alz.70572.
6
U1-70K and U1A and tau pathogenesis in demented and non-demented individuals with Down syndrome.
Alzheimers Dement. 2025 Aug;21(8):e70474. doi: 10.1002/alz.70474.
8
Age and sex are associated with Alzheimer's disease neuropathology in Down syndrome.
Alzheimers Dement. 2025 Jul;21(7):e70408. doi: 10.1002/alz.70408.

本文引用的文献

1
Down syndrome and Alzheimer's disease: Common pathways, common goals.
Alzheimers Dement. 2015 Jun;11(6):700-9. doi: 10.1016/j.jalz.2014.10.007. Epub 2014 Dec 12.
2
Vascular contributions to cognitive impairment and dementia including Alzheimer's disease.
Alzheimers Dement. 2015 Jun;11(6):710-7. doi: 10.1016/j.jalz.2014.10.008. Epub 2014 Dec 12.
4
Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid.
Neurodegener Dis. 2014;14(2):98-106. doi: 10.1159/000358800. Epub 2014 Jun 27.
5
Alzheimer's disease risk genes and mechanisms of disease pathogenesis.
Biol Psychiatry. 2015 Jan 1;77(1):43-51. doi: 10.1016/j.biopsych.2014.05.006. Epub 2014 May 17.
7
Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome.
Neuromolecular Med. 2014 Jun;16(2):510-6. doi: 10.1007/s12017-014-8302-1. Epub 2014 Apr 18.
8
Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.
Free Radic Biol Med. 2014 Jun;71:270-280. doi: 10.1016/j.freeradbiomed.2014.03.027. Epub 2014 Mar 25.
9
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.
Biochem Pharmacol. 2014 Apr 15;88(4):640-51. doi: 10.1016/j.bcp.2013.12.024. Epub 2014 Jan 4.
10
Cerebral microbleeds are related to loss of white matter structural integrity.
Neurology. 2013 Nov 26;81(22):1930-7. doi: 10.1212/01.wnl.0000436609.20587.65. Epub 2013 Oct 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验